<DOC>
	<DOCNO>NCT02052882</DOCNO>
	<brief_summary>This study determine use weekly romiplostim injection improve patient 's platelet count effectively simply wait platelet improve , romiplostim also allow patient receive least 2 cycle chemotherapy without thrombocytopenia .</brief_summary>
	<brief_title>Study Romiplostim Chemotherapy Induced Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>1 . Patients ( 18 year age great ) active nonhematological cancer : A . The patient previously receive chemotherapy regimen include one follow agent : 1 . Nucleoside Analogue , include gemcitabine fluorouracil 2 . Carboplatin cisplatin 3 . Anthracycline 4 . Alkylating agent 5 . Other chemotherapy agent thrombocytopenia known common toxicity . 2 . Patients cytotoxic chemotherapy within 14 day begin study . 3 . Thrombocytopenia : . A . Defined platelet count &lt; 100,000/mcL . B . The patient least 2 CBCs platelet count &lt; 100,000/mcL separate least 4 week , platelet count ≥100,000/mcL prior 6 week period , despite ( 1 ) delay , ( 2 ) modification chemotherapeutic regimen . C. A platelet count &gt; 100,000/mcL , follow within 7 day platelet transfusion , make patient ineligible , long one subsequent platelet count confirm thrombocytopenia ( &lt; 100,000/mcL ) . D. Patients undergone bone marrow aspirate biopsy peripheral blood test prior 3 month without evidence leukemia myelodysplasia fluorescent situhybridization ( FISH ) E. Dysplastic change , base morphology , exclude patient FISH panel MDS normal . 4.KPS ≥ 50 ECOG performance status ≤2 . 5.Ability provide write informed consent . 1 . Patients history hematologic malignancy , include leukemia , myeloma , myeloproliferative disease , lymphoma , myelodysplastic disease . 2 . Anemia ( Hgb &lt; 8.0 gm/dl ) leukopenia ( absolute neutrophil count ( ANC ) &lt; 1,000/mcL ) . Use red cell transfusion , erythropoietin , GCSF , order manage oncology service , acceptable preclude participation . 3 . Patients underlie liver disease , cirrhosis chronic hepatitis , primary metastatic cancer liver exclude ALT/AST &gt; 3X ULN Total Bili &gt; 3X ULN . In presence primary metastatic liver cancer , patient exclude ALT/AST &gt; 5X ULN Total Bili &gt; 5X ULN 4 . Patients history prior symptomatic venous thrombotic event , DVT pulmonary embolism symptomatic arterial thrombotic event myocardial infarction , ischemic cerebral vascular accident transient ischemic attack ineligible tolerate anticoagulation therapy . If patient remain anticoagulation , complete prescribed course anticoagulation , eligible enrollment . A venous thrombotic event associate central venous catheter make patient ineligible . 5 . Serious concomitant medical condition could interfere conduct clinical trial , unstable angina , renal failure require hemodialysis , active infection require IV antibiotic 6 . Pregnant women/lactating mother 7 . Patients unwilling use contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Romiplostim</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>13-132</keyword>
</DOC>